EP3036003A1

EP3036003A1 - Diffusion pigments in phototherapy

Info

Publication number: EP3036003A1
Application number: EP14747514.9A
Authority: EP
Inventors: Corinna Wirth
Original assignee: Merck Patent GmbH
Current assignee: Merck Patent GmbH
Priority date: 2013-08-22
Filing date: 2014-07-18
Publication date: 2016-06-29
Also published as: CN105451815A; KR20160045856A; JP2016528263A; US20160199492A1; WO2015024615A1

Abstract

The present invention relates to the use of microfine pigments in medical and cosmetic phototherapy.

Description

Diffusion pigments in phototherapy

The present invention relates to the use of microfine pigments to improve the light output in phototherapy. Phototherapy represents a possibility of the physical treatment of the skin. Here, the health-promoting properties of light of different wavelengths are used. Phototherapy finds its application in both medicine and cosmetics. Many factors, such as Smoking, stress, sun, alcohol, air pollution and diseases cause the skin to age prematurely and cause wrinkles. Such changes can also be attributed to natural aging processes of the skin. Targeted phototherapy in cosmetics revitalizes the skin and supports a healthy and radiant appearance. Specific wavelength light generated by, for example, light emitting diodes (LEDs) or organic electroluminescent devices such as organic light emitting diodes (OLEDs) or organic light emitting electrochemical cells (OLECs, LECs, or LEECs) stimulates collagen production of the cells and activates cell growth. The increased formation of collagen results in wrinkles being reduced and the skin looking younger, healthier and more vital. At the same time, targeted phototherapy inhibits enzymes that break down collagen, thereby accelerating the aging process. A complete treatment usually lasts only a few minutes, is painless and is often even perceived as pleasant. Typical cosmetic applications include the treatment or prevention of skin aging (skin aging, anti-aging), skin wrinkles, acne, comedones and cellulites.

In addition to the cosmetic application areas for phototherapy, it also exists a variety of medical or therapeutic

Application areas. Psoriasis, atopic dermatitis, atopic eczema, vitiligo, jaundice, neonatal itch, itching of the skin, vitiligo, and many other skin inflammatory diseases become phototherapeutic 1968

- 2 - treated. But also in pain therapy or in the treatment of tumors and in cancer therapy, phototherapy is widely used.

The skin has a pronounced facial expression in addition to the visible facial expression

Micro-age structure on. This results in the typical skin relief with more or less pronounced valleys. As a result, the actual skin surface is significantly larger than the planar projection it depicts. However, this also means that in the case of a phototherapeutic treatment of the skin, the areas of the skin lying in the valleys are irradiated less intensely than the areas which lie outside the valleys on the surface of the skin. In a phototherapeutic treatment, this means that the lying in the valleys areas are not optimally irradiated. Or, as a result, in those cases where the skin areas lying in the valleys are sufficiently irradiated, the areas lying outside the valleys on the surface of the skin are too intensively irradiated. As a result, the skin texture impedes a uniform illumination of the entire available surface. Often, higher doses of light must be administered, which can lead to increased side effects from phototherapy. This considerably limits the possibilities of phototherapy.

On this basis, it is an object of the present invention to improve the cosmetic and medical phototherapeutic treatment in such a way that a uniform illumination of the entire skin is achieved.

The present object is achieved by the features of claim 1. Further advantageous embodiments of the invention are the subject of the dependent claims.

The present invention achieves the stated object in that the pigments used in phototherapy comprise diffusion pigments. The inventive use of diffusion pigments, a significant improvement in phototherapy is achieved by a Overriding the illuminated area avoided and the optimal biological use of the light is ensured. The technical teaching according to the invention makes it possible to use lower light intensities in order to achieve the same effect with fewer side effects, or it is possible to achieve a higher effect of the phototherapy with the same light intensities. On the one hand, the higher light intensities can be used to increase the effect of the radiation at the site of action. On the other hand, the higher light intensities at the site of action can also be used to reduce the irradiation time.

Diffusion pigments are counted among the cosmetic fillers and are characterized by the fact that they have an irregular surface. The irregular surface has the consequence that incident light reflects irregularly, and thus diffuses, so is scattered. This effect is also referred to as a soft focus effect or "soft focus effect." Diffusion pigments with these effects are sometimes referred to as "soft focus fillers."

A typical example of a diffusion pigment (Soft Focus Filier) is the pigment Ronasphere® LDP from Merck KGaA. Ronasphere® LDP is a functional filler consisting of silica globules that are irregularly coated with titanium dioxide and iron oxide. As a result of this coating, the beads have a light-diffusing, and almost no reflective effect. Their refractive index is close to that of the skin. When applied to the skin, they are almost invisible due to the lack of reflective effect. The light diffusion properties of Ronasphere® LDP allow the formulation of skin care compounds and decorative cosmetics with special optical effects.

The light-diffusing properties help to visually correct fine lines and wrinkles. These microspheres are also used as a galenic adjuvant because they help increase the viscosity in aqueous compositions, thereby avoiding the use of additional thickeners or gelling aids can. With mild stirring, the particles can be easily dispersed in water or oil. 80% of Ronasphere® LDP particles have a particle size of less than 25 microns, the average size is 4.0 to 7.0 microns. Silicone-based formulations are often characterized by a very special, elegant and pleasant feel on the skin, but for cost reasons they can not always be fully implemented in formulations. A sensory approach in this direction is also possible in these cases through targeted use of spherical pigments. The Soft Focus effect is best supported by the use of spherical substances.

By using the diffusion pigments according to the invention, the available photons are used more efficiently. It could surprisingly be shown that the diffusion pigments used not only scatter daylight, thereby making skin lines appear softer, but also distribute the light or radiation of an artificial radiation source used in a phototherapeutic treatment of the skin in such a way that the skin of the in the valleys lying areas are irradiated more intensely compared with the state of the art than the areas outside the valleys on the

Surface of the skin are. In a phototherapeutic treatment, this results in the result that all areas of the skin are sufficiently irradiated.

The light intensity of phototherapy can therefore be reduced, resulting in a shorter irradiation time or a lower operating temperature of the lighting device on the positive

Treatment comfort affects.

Furthermore, the use of soft focus filing allows that

Be used for phototherapy, which were previously not considered for this purpose due to their low radiation intensity for this purpose. Likewise, the warming effect of the light (for example, IR

Radiation) can be utilized more efficiently, since the inventive use of the diffusion pigments causes an increased heat transfer into the skin and thus the tissue. For the purpose of phototherapy, basically any radiation source can be used. It is preferred if an artificial radiation source is used for phototherapy. Typical artificial radiation sources used in phototherapy are conventional lamps, UV lamps, fluorescent tubes, lasers or LEDs. Another class of radiation sources are the organic electroluminescent devices. The organic electroluminescent devices include in particular the organic light-emitting diodes (OLED), the organic light-emitting transistors, the organic light-emitting electrochemical cells (OLEC, LEC or LEEC) and the organic laser diodes , Among the organic electroluminescent devices, the OLEDs and OLECs are particularly preferred for the purposes of the present invention, and the OLEDs are very particularly preferred. It is not difficult for a person skilled in the art from a large repertoire of radiation sources to select the radiation source suitable for the particular purpose. [For example, for stationary applications, which are preferably performed in medical or cosmetic facilities, conventional lamps, UV lamps, fluorescent tubes, lasers or LEDs are often used. For private use or mobile use, organic electroluminescent devices are particularly suitable because of their small size and flexibility of the devices. Organic electroluminescent devices are also suitable for stationary applications.

Furthermore, it is not difficult for the person skilled in the art to select the suitable wavelength for the respective phototherapeutic application. There are numerous publications on this, the specific wavelengths or ranges of wavelengths for phototherapeutic Recommend treatment and have been proven in therapy now.

It is preferred for the purposes of the present invention, when the

Radiation source emitted radiation of a wavelength in the range of 250 nm to 1500 nm.

For the treatment of acne blue light is most preferred. It is particularly preferred if the radiation source is blue light of wavelength 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409 , 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, and 430 nm, for treating acne. 414 and 415 nm are of particular interest to kill P. acnes bacteria. Treatment means both treatment of existing circumstances (for example acne) and prophylaxis.

Studies on the treatment of acne have revealed that its combination of different wavelengths is particularly well suited to effectively treat acne. In this case, a combination of blue and red light is particularly preferred. The red light is preferred

selected from the wavelength range of 590 to 750 nm, more preferably from the range of 600 to 720 nm and most preferably from the range of 620 to 700 nm. Particularly preferred are the wavelengths 633 and 660 nm. The blue light can from the above be selected wavelengths.

For the treatment of comedones, a wavelength of 500 nm or light in the range of 500 and 700 nm is preferred.

For the treatment of cellulitis is preferably a wavelength in

Range of 400 and 1000 nm, most preferably used in the range of 400 and 900 nm, more preferably in the range of 450 and 900 nm and most preferably in the range of 500 and 850 nm. For the treatment of skin aging, a wavelength in the range of 400 and 950 nm, more preferably in the range of 550 and 900 nm and particularly preferably in the range of 550 and 860 is preferably used.

Furthermore, for the treatment of skin aging in a preferred embodiment of the present invention, wavelengths in the range of 600 nm and 650 nm, more preferably in the range of 620 nm and 650 nm are used.

Further preferred for the treatment of skin aging is when the

Radiation source light radiation in the range of 350 and 950 nm, most preferably emitted in the range of 380 and 900 nm and more preferably in the range of 400 and 900 nm.

For the purpose of treating skin aging, blue light is particularly preferred.

Further particularly preferred wavelengths for the treatment of skin aging are 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, and 430 nm. 415 nm is included a particularly preferred wavelength.

For the treatment of dermatitis is preferably a wavelength in

Range of 470 and 670 nm, most preferably used in the range of 490 and 650 nm, and more preferably in the range of 530 and 610 nm. Two particularly preferred wavelengths for the treatment of dermatitis are 550 nm and 590 nm.

For the treatment of atopic eczema is preferred one

Wavelength in the range of 470 and 670 nm, more preferably used in the range of 490 and 650 nm, and particularly preferably in the range of 530 and 610 nm. A most preferred wavelength in this context is 320 nm. For the treatment of psoriasis, a wavelength in the range of 240 and 500 nm, more preferably in the range of 290 and 400 nm and particularly preferably in the range of 300 and 330 nm, is preferably used. Two most preferred wavelengths in this context are 311 nm and 320 nm

For the treatment of vitiligo, a wavelength in the range of 240 and 500 nm, more preferably in the range of 290 and 400 nm and particularly preferably in the range of 300 and 330 nm, is preferably used. A most preferred wavelength in this context is 311 nm.

For the treatment of edema, a wavelength in the range of 760 and 940 nm, more preferably in the range of 780 and 920 nm, particularly preferably in the range of 800 and 900 nm and most preferably in the range of 820 and 880 nm is preferably used. A most preferred wavelength in this context is 850 nm.

For the treatment of inflammations, a wavelength in the range of 350 and 900 nm, more preferably in the range of 380 and 900 nm and particularly preferably in the range of 400 and 860 nm, is preferably used. Very particularly preferred wavelengths in this

The connection is 405 nm, 420 nm and 850 nm.

For the treatment of hair loss (alopecia) is preferred one

Wavelength in the range of 240 and 500 nm, more preferably used in the range of 290 and 400 nm, and particularly preferably in the range of 300 and 330 nm. A particularly preferred wavelength in this context is 311 nm. For the treatment of jaundice and Neonataliketrus is preferably a

Wavelength in the range of 300 and 700 nm, more preferably in the range of 350 and 600 nm, particularly preferably in the range of 370 and

580 nm, most preferably used in the range of 400 and 550 nm, and particularly preferably in the range of 410 and 470 nm. Two most preferred wavelengths in this context are 450 and 466 nm.

For some applications it may be advantageous if the phototherapeutic irradiation of the skin is continuous, whereas in other applications pulsed irradiation is desirable. Typical pulse sequences can be deduced by the person skilled in the art from the state of the art. In WO 2003/086215 A1, for example in Example 1, preferred pulse sequences for the reduction of skin folds are described. In a preferred embodiment, the phototherapy is carried out by means of organic electroluminescent devices, preferably by means of OLEDs and / or OLECs. An advantage of organic electroluminescent devices is that they are thin-film devices made of organic materials which, in contrast to LEDs, have a lower current density, lower luminance and do not require monocrystalline materials. The organic electroluminescent devices can be produced on flexible carriers, are surface radiators and can be produced in any desired fit for parts of the body to be irradiated. Details of said devices are well known in the art. The wavelengths of said devices can be determined by the skilled person by suitable selection of fluorescent or phosphorescent emitters or color converters without inventive step to the respective cosmetic or

be adapted to medical requirements. One advantage of OLECs over OLEDs is the simpler design and the

Use of less harmful materials. OLECs are usually more cost-effective to manufacture and are due to the usually shorter life compared to the life of the OLEDs, especially for short-lived products that are used only once or a few times, such as paving. The energy supply for the organic electroluminescent devices can be done by a power supply, but also by means of a separate power supply on the basis of a small battery or in the form of a printed battery. A typical structure of an OLED is disclosed in WO 90/13148 A1. Further details on OLEDs can also be found in J. Shinar, Organic Light-Emitting Devices, Springer Verlag 2004. OLECs are, for example, by Qibing Pei et al. in Science, 1995, 269, 1086-1088 and in WO 2012/045384 A1.

The properties of a diffusion pigment (Soft Focus Filier) can be clearly described by the Soft Focus Factor (SFF). The SFF depends on two major optical properties, whiteness and matting effect. The quantification of SFF is described in detail in WO 2012/031665 A1 using a goniochromatic measurement method. The values given here for SFF are determined by this method. Thus, SFF is defined as the quantum of Lw and Lg (SFF = Lw / Lg), where Lw is the brightness value L ^* at 65 ° and Lg is the L * value in the glancing angle. Further details on the parameters and the implementation of the measuring method can be found in the disclosure of WO 2012/031665 A1. Ideally, the soft focus factor is 1.

It is preferred for the purposes of the present invention, if the

The diffusion pigment used according to the invention has an SFF in the range from 0.5 to 1, very preferably in the range from 0.6 to 1, particularly preferably in the range from 0.65 to 1, very particularly preferably from 0.7 to 1, particularly preferably in the range from 0.75 to 1, more preferably in the range of 0.8 to 1, and most preferably in the range of 0.85 to 1.

It is of particular advantage if the diffusion pigments comprise at least one substance which is selected from the group of the following substances: powder preparations of silica and silicates, talc, powder formulations of polyethylenes, powder preparations of starch, powder formulations of polyamides, powder preparations of styrenes and / or Acrylic copolymers, silicone elastomers, aluminum silicate powder, polymethylmethacrylate (PMMA) type powder formulations, talc, silica and T1O2 or silica compositions and zinc oxide, polyethylene powder, starch powder, polyamyd powder, styrene and acrylic copolymer compositions,

Silicone elastomers and mixtures thereof. Also the following compounds can be used by way of example: talc with an average size of less than 3 ^μι η, talc having an average size of less than 1, 8 pm, TALC P3.RTM by Nippon Tale; NYLON. RTM 12 powder, ORGASOL 2002 EXTRA D NAT COS.RTM from Atochem, silica particles whose surface was treated with 1 to 2% mineral wax, for example from Degussa, amorphous silica microspheres such as the type SUNSPEHRE (reference H-53) from Asahi Glass, as well

Microbeads such as SB-700.RTM or SB-150.RTM from Miyoshi. As advantageous for the cosmetic or medical application, a composition for phototherapy has been found, the

Composition comprises at least one cosmetic base or a pharmaceutical base and diffusion pigments. Depending on

Skin texture and cosmetic or medical target

Treatment, different proportions of diffusion pigments can be used.

The person skilled in the art is well aware of the preparation of the compositions of the prior art. Examples of corresponding preparations are disclosed in WO 00/15720 A1, WO 01/16235 A1 or in WO 2012/031664 A1 and in the examples.

In a further preferred embodiment of the present invention

Invention, the cosmetic composition contains at least one cosmetic active ingredient. As a result, the effect of the phototherapeutic radiation can be further increased.

In a further preferred embodiment of the present invention

Invention, the pharmaceutical composition contains at least one pharmaceutical agent. As a result, the effect of the phototherapeutic radiation can be further increased.

In addition, it has proved to be advantageous if a

Composition comprising at least comprising a diffusion pigment is used as a drug. Cosmetic or medical phototherapy can be further improved by treating the skin to be irradiated with skin lightening

Compounds is treated. Skin-lightening compound is understood as meaning all compounds which are understood as such according to WO 2013/060407 A1. The treatment of the skin with a skin-lightening compound is preferably carried out before the phototherapeutic treatment of the skin with the diffusion pigment, but can also take place at the same time. The treatment of the skin with a skin lightening compound has the technical effect that more radiation from the radiation source can penetrate into the skin layers. The technical effect of the invention due to the use of diffusion pigments in phototherapy can thus be further increased by the additional use of skin lightening compounds. Further details on the use of skin lightening compounds can be found in the disclosure of WO 2013/060407 A1.

The combined use of diffusion pigments and skin lightening compounds in phototherapy for the treatment of jaundice, preferably of neonatal jaundice in neonates with skin types II to VI, more preferably with skin types IV to VI and particularly preferably with skin types V to VI (WO 2013/060407 A1).

The present invention therefore also relates to a composition comprising at least one diffusion pigment and at least one skin-lightening compound.

The present invention also relates to a method for the cosmetic or medical treatment of human or animal skin comprising the steps of 1) treating the skin with a skin-lightening compound 2) treating the skin with a diffusion pigment and 3) irradiating the skin with a radiation source.

The skilled worker is aware that the skin lightening compounds, as well as the diffusion pigments in general with the aid of appropriate medical or cosmetic compositions are applied.

The present invention furthermore relates to a kit consisting of a composition comprising at least one diffusion pigment and a composition comprising at least one skin-lightening agent

Connection.

In a preferred embodiment, the kit also includes an artificial radiation source, which is most preferably selected from the above-mentioned radiation sources.

It is of particular advantage when the treatment of

Skin diseases by phototherapy takes place. Particularly advantageous is a cosmetic method for

A skin enhancement comprising the steps of preparing the skin, applying a composition comprising diffusion pigments, and irradiating the skin with light. It is particularly advantageous if in the cosmetic process, the irradiation by means of OLED and / or OLEC takes place.

The technical teaching according to the invention is distinguished by one or more of the following surprising advantages over the prior art:

1. The technical teaching of the invention allows, while retaining the effect, to reduce the light intensity emitted by the radiation source for a phototherapeutic application in medicine and / or cosmetics. Side effects of phototherapeutic applications can be reduced.

2. The fact that lower radiation intensities are required, the use of modern radiation sources, such as the organic Electroluminescent devices, further driven.

The fact that lower radiation intensities are required, energy can be saved.

The technical teaching of the invention allows the use of mobile radiation sources with low energy consumption.

The technical teaching of the invention allows the

Increase radiation intensity and thus the effect at the site of action, without the intensity of the radiation emitted by the radiation source is increased.

By reaching the point of action of the radiation higher radiation intensity, the irradiation time can be reduced, which has a positive effect on the reduction of side effects and for the person to be irradiated means a higher level of comfort.

These advantages mentioned above are not accompanied by a deterioration of the other electronic properties.

The abovementioned preferred embodiments can be combined with one another as desired. In a particularly preferred embodiment of the invention, the abovementioned preferred embodiments apply simultaneously.

It should be understood that variations of the embodiments described in the present invention are within the scope of this invention. Each feature disclosed in the present invention may be provided with alternative features, the same, an equivalent or the like, unless explicitly excluded

Serve purpose, be exchanged. Thus, unless otherwise stated, each feature disclosed in the present invention is to be considered as an example of a generic series or as an equivalent or similar feature. All features of the present invention may be combined in any manner, unless certain features and / or steps are mutually exclusive. This is especially true for preferred features of the present invention. Likewise, features of non-essential combinations can be used separately (and not in combination).

It should also be understood that many of the features, and particularly those of the preferred embodiments of the present invention, are themselves inventive and not merely to be considered part of the embodiments of the present invention. For these features, independent protection may be desired in addition to or as an alternative to any presently claimed invention.

The teaching on technical action disclosed with the present invention can be abstracted and combined with other examples.

The skilled person can develop from the descriptions without inventive step further phototherapeutic applications according to the invention and thus carry out the invention in the entire claimed area.

The following examples and illustrations describe by way of example

Embodiments of the invention. These examples are for the

Illustrate the invention and are not to be understood in a limiting sense.

Figure 1 shows the transmission in% as a function of the wavelength in nm of treated and untreated PMMA plates. The upper line (solid line) shows the values for untreated PMMA plates

(PMMA_1), the line (dotted) the data of Ronaflair® LDP white treated PMMA plates (LDP_1).

Figure 2 shows the transmission in% as a function of the wavelength in nm of treated and untreated PMMA plates. The upper line (solid line) shows the values for untreated PMMA plates, the T EP2014 / 001968

- 16 - bottom line (dotted) the data of OrgaSol-treated PMMA plates.

Figure 3 shows the% reflectance as a function of wavelength in nm. The top line at 700 nm shows the values for placebo (dashed), the middle line (solid line) the values for orgasol and the below line (dotted) those for Ronaflair® ,

Examples Example 1

In vivo test: heat input into the skin Two commercially available red light lamps (Philips HP 3616/01 INFRAPHIL) are placed at a height of 25 cm above that on a table

Back of a volunteer firmly mounted. Parallel is now the

Temperature perception of one hand A (treated as a control with base cream) compared with the other B (treated with a base cream containing 8% Ronaflair® LDP white (Merck KGaA)). It was found that the temperature of the back of the hand B is perceived as warmer.

Formulations containing other diffusion pigments show the same properties. Ronaflair® LDP white is a preparation of silica with a Ti0 ₂ / Fe203 coating.

Example 2

Polymethyl methacrylate (1 mm thick) plates are roughened to simulate a skin surface profile. Now the transmission is measured between 400 and 800 nm in a spectrometer. For this purpose, an untreated plate as a comparison and a plate, coated with

Ronaflair® LDP white (SFF = 0.89), compared. It was shown (Figure 1) that the direct transmission through the filter is reduced

Light rays are broken off from the radiation source, causing the

Scattering of the incident light proves. The diffusion pigment itself is transparent and can not explain the reduced transparency due to light absorption.

The experiments are carried out with other diffusion pigments and show a comparably good effect. Figure 2 shows the effect of using OrgaSol (SFF = 0.84). Analogous, good results are also obtained with RonaFlair® ExtenderW (Merck KGaA, SFF = 0.8), TRES BN PUHP3016 (Saint-Gobain, SFF = 0.84) and Coverleaf AR80 (Presperse, Inc., SFF = 0.82) , Conventional fillers (eg RonaFlair® Micra M (Merck KGaA, SFF = 0.15) or talc (MerckKGaA, SFF = 0.21)) show a significantly lower ability to distribute incident light.

Example 3

in vivo human experiment

In a male, volunteer subject, three equal areas are recorded on the inside of the forearm and treated with a control formulation and two verum formulations of a defined application amount.

By means of commercially available emission measurement by means of a remission probe, the amount of light reflected back from the skin surface is quantified. As a control is a commercial formulation (Ombia natural brine ointment), which has no particulate ingredients. 5% Orgasol or 5% Ronaflair® LDP white are added to this formulation in each case.

In each case 1 pL / cm ^{2 are applied} .

It turns out that the remission of the placebo formulation is greater than that of the verum formulations. This stands by a diminished

Remission provides more light in the skin resulting in better biological efficacy (Figure 3).

Example 4

Preparation of a formulation comprising diffusion pigments

4.1 Preparation of a mixture comprising diffusion pigments

122.7 g of spherical silica (Ronaflair® LDP white) are suspended in 2277 g of demineralized water and the suspension is heated to 75 ° C. Then 88.5 g of titanium tetrachloride solution (TiCU content: 64.4% by weight) are metered in with 90 g of demineralized water over a period of 60 minutes. With 32% sodium hydroxide solution, the pH is kept constant at 2.2 to 2.3. After the titanium tetrachloride solution has been added, the pH is adjusted to 3.2. Subsequently, 50.4 g 68

- 19 -

Iron (III) chloride solution diluted with 50.4 g of water,

added, keeping the pH at 3.2 to 3.2. The mixture is then stirred for 15 minutes and the pH is adjusted to 7.0.

Overnight, the suspension is allowed to cool and settle. The solution located above the bottom body is decanted off and discarded. The soil body is isolated on a suction filter, washed free of salt with 5 L demineralized water, dried overnight at 110 ° C in a drying oven and passed through a 0.3 mm sieve. 154 g of component B are obtained.

9.2 kg of spherical silicon dioxide (Ronaflair® LDP white) are suspended in 170 l demineralized water and the suspension is heated to 75 ° C. with stirring. Then 10.43 L titanium tetrachloride solution is diluted with 3 L demineralized water and over a period of 60 min. added to the suspension. By adding 32%

Sodium hydroxide solution, the pH is kept constant at 2.2 to 2.3. After metering in the titanium tetrachloride solution, stirring is continued for 15 minutes and the pH is adjusted to 7.0. The component A thus prepared is left in the reactor.

Subsequently, 715 g of the dried and sieved component B are added to the suspension of component A in the reactor. The

Mixture is 15 min. stirred and allowed to cool overnight and allowed to sit. After decanting off the supernatant solution, the soil body is filtered through a monolayer filter and 1000 L

washed salt-free demineralized water. The resulting pigment is dried overnight at 110 ° C and calcined at 650 ° C in a rotary oven with a residence time of 15 minutes. You get a off-white powder with its very good skin feel.

4.2 Preparation of a cosmetic foundation

For the preparation of a cosmetic base in a first phase A 7 wt .-% caprylic / capric triglyceride, 4 wt .-% refined jojoba wax, 6 wt .-% ethyl hexylene stearate, 2 wt .-% Glycerol monostearate, 2 wt .-% Generol R, that is the specified

Mixture of phytosterols, as well as 1, 5 wt .-% polyglycerol-3-methylglucose distearate produced. In heated water with a

Weight fraction of 59.75 wt .-% are 0.15 wt .-% carboxymethyl, 0.15 wt .-% acrylic acid vinyl ester copolymer, 4 wt .-% 86.5% glycerol, 2 wt % Urea and 0.1% by weight

Sodium hyaluronate introduced. The resulting phase B is heated further and added again with gentle stirring of phase A.

The resulting mixed phase of phases A and B is added with gentle stirring as phase C 5 wt .-% SK-Influx, ie a mixture of

Added ceramides, carbomers and xanthan. After homogenizing the resulting mixture, this is cooled to about 40 ° C.

4.3 Completion of the preparation

Depending on the nature of the skin, 2 to 5% by weight of the mixture comprising diffusion pigments are now added to the cosmetic base; Finally, the resulting preparation is homogenized. Analogously, compositions for pharmaceutical use can be prepared. The present invention decisively improves the possibilities of phototherapeutic skin treatment and thus extends its cosmetic and medical possibilities.

Claims

claims

Diffusion pigment for use in medicine in combination with phototherapy.

Diffusion pigment according to claim 1 for use in

Treatment of human or animal skin.

A diffusion pigment according to claim 1 or 2 for use in the treatment of psoriasis, atopic dermatitis, atopic eczema, jaundice, neonatal jaundice, vitiligo, edema, tumors, inflammation, depression, pain and seasons depression.

Diffusion pigment according to one or more of Claims 1 to 3, characterized in that the soft focus factor (SFF) of the diffusion pigment is in the range of 0.5 to 1, more preferably in the range of 0.6 to 1, particularly preferably in the range of 0 , 65 to 1, most preferably from 0.7 to 1, more preferably in the range of 0.75 to 1, even more preferably in the range of 0.8 to 1 and most preferably in the range of 0.85 to 1.

Diffusion pigment according to one or more of claims 1 to 3, characterized in that the radiation source is selected from the group consisting of a conventional lamp, UV lamp, laser, fluorescent tube, LED and the organic electroluminescent devices, preferably the OLEDs and OLECs.

Diffusion pigment according to one or more of claims 1 to 3, characterized in that the diffusion pigment comprises at least one compound selected from a group comprising powder formulations of silica and silicates, powder formulations of polymethyl methacrylates, talc, compositions of silica and Τ1Ό2, compositions of silica and zinc oxide, powder formulations of polyethylenes, powder preparations of starch, powder formulations of polyamides, powder preparations of styrenes, acrylic copolymers and silicone elastomers.

7. Diffusion pigment according to one or more of claims 1 to 6, characterized in that in addition a skin-lightening compound is used.

Cosmetic use of diffusion pigments in combination with phototherapy of the skin.

Cosmetic use according to claim 8, characterized

characterized in that the soft focus factor (SFF) of the diffusion pigments is in the range of 0.5 to 1, more preferably in the range of 0.6 to 1, more preferably in the range of 0.65 to 1, most preferably of 0.7 to 1, more preferably in the range of 0.75 to 1, even more preferably in the range of 0.8 to 1, and most preferably in the range of 0.85 to 1.

Cosmetic use according to claim 8 or 9 for the treatment and prevention of acne, cellulite, skin aging and skin wrinkles.

Cosmetic use according to one or more of

Claims 8 to 10, characterized in that the skin is additionally treated with a skin-lightening compound.

Use of diffusion pigments in phototherapy, characterized in that the soft focus factor (SFF) of the diffusion pigments is in the range of 0.5 to 1, more preferably in the range of 0.6 to, more preferably in the range of 0.65 to 1, most preferably from 0.7 to 1, more preferably in the range of 0.75 to 1, even more preferably in the range of 0.8 to 1 and most preferably in the range of 0.85 to 1

13. A cosmetic procedure for skin improvement comprising the

Steps Applying a composition or formulation comprising the diffusion pigment and irradiating the skin with an artificial radiation source

Composition comprising at least one diffusion factor having a soft focus factor (SFF) in the range of 0.5 to 1, more preferably in the range of 0.6 to 1, particularly preferably in the range of 0.65 to 1, most preferably of 0.7 to 1,

more preferably in the range of 0.75 to 1, more preferably in the range of 0.8 to 1 and most preferably in the range of 0.85 to 1 and at least one skin lightening compound.

15. A kit comprising a composition comprising at least one skin-lightening compound and a composition comprising at least one diffusion pigment.

16. Kit according to claim 15 additionally containing an artificial

Radiation source.

17. A composition according to claim 14 or a kit according to claim 15 or 16 for use in medicine in combination with

Phototherapy.

18. Cosmetic use of a composition according to claim 14 or a kit according to claim 15 or 16 in phototherapy.